RE: NCI gold!!17 Sep 2025 07:12
Dr. Adrian Kinkaid, CEO of Fusion Antibodies plc, commented: "We are extremely pleased with the performance of the OptiMAL® platform to date. In some ways it has exceeded our aspirations. It is also most gratifying that the NCI, our key collaborators in the validation process, wish to continue using OptiMAL® for years to come. I am confident this will help them fulfil their mission and to progress multiple therapeutic and diagnostic projects targeting the widest range of cancers."